Ayala Pharmaceuticals (AYLA) sets IPO terms

Ayala Pharmaceuticals (AYLA) has filed an updated preliminary prospectus for its IPO of ~3.3M common shares at $14 - 16 per share.
Underwriters' over-allotment will be up to an additional 500K shares.

The Rehovet, Israel-based biopharmaceutical outfit develops treatments for rare and aggressive cancers by leveraging its bioinformatics platform and next-gen sequencing.

https://www.ayalapharma.com/